<DOC>
	<DOCNO>NCT00362349</DOCNO>
	<brief_summary>Idiopathic Thrombocytopenic Purpura ( ITP ) autoimmune bleed disorder characterise isolated low platelet count . The aim treat patient ITP increase platelet concentration reduce risk bleeding . A number control multi-centre study demonstrate Intravenous Immunoglobulin ( IVIg ) therapy produce rapid rise platelet count within 24 72 hour period . This study evaluate efficacy safety Ig NextGen 10 % adult patient ITP .</brief_summary>
	<brief_title>Ig NextGen 10 % Idiopathic Thrombocytopenic Purpura ( ITP ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>clinical diagnosis ITP platelet count &lt; 50 X 10^9 plan splenectomy previous nonresponders IVIg treatment know suspected hypersensitivity previous evidence severe side effect immunoglobulin therapy patient receive treatment : 1 . IVIg antiD immunoglobulin 2. immunosuppressive , immunomodulatory drug ( ) active treatment ( ) ITP within three week prior first day study drug administration 3. patient receive IV administration steroid OR change oral corticosteroid treatment OR danazol within 15 day prior first day study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>ITP</keyword>
	<keyword>IVIg</keyword>
	<keyword>Platelet count</keyword>
	<keyword>Bleeding</keyword>
</DOC>